Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block

Not Applicable

Not yet recruiting

• Conditions: Post Operative Pain
• Interventions: Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block

• Registration Number: NCT06624319
• Lead Sponsor: Assiut University

Brief Summary

The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.

Detailed Description

The transversus abdominis plane (TAP) involves innervations of the anterolateral abdominal wall derived from T6-L1. The block can be given either by anatomical landmark technique or by using an ultrasound probe. The local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle. It provides adequate postoperative analgesia following various abdominal surgeries.Dexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief .In previous studies, the addition of dexmedetomidine to bupivacaine in the TAP block has prolonged the effect of this block . So far, the optimal dose of dexmedetomidine for the TAP block has not been determined.

Study Timeline

• Study First Submitted: 2024-09-28
• Status Verified: 2024-10
• Study First Submitted QC: 2024-10-01
• Study First Posted: 2024-10-02
• Last Update Submitted: 2024-10-02
• Last Update Posted: 2024-10-03
• Study Start: 2025-01
• Primary Completion: 2026-01
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• age from 18 to 65 years old
• lower abdominal cancer surgery

Exclusion Criteria

• patient refusal
• the local anesthetic allergy
• coagulopathy
• local infection at the procedure site
• psychic patients
• patient on chronic opioid use

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
tap block with 0.5 μg/kg dexmedetomidine	Dexmedetomidine as adjuvent to bupvacaine in tap block	will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
tap block with 1.5 μg/kg dexmedetomidine	Dexmedetomidine as adjuvent to bupvacaine in tap block	will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Primary Outcome Measures

Name	Time	Method
Total morphine consumption during the first 24 hours postoperatively	First 24 hours postoperative	Morphine consumption during the First 24 hours postoperative

Secondary Outcome Measures

Name	Time	Method
Severity of pain using Visual analogue scale	First 24 hours postoperative	The severity of pain at rest and on coughing will be assesd using a 10-cm vas(0 means no pain ,10 means worst pain)
Patient level of sedation using four point modified ramsy scale	First 24 hours postoperative	using a 4-point scale (0 = awake and alert, 1 = minimally sedated, responds to speech, 2 = moderately sedated, arousable by tactile stimulation, and 3 = deeply sedated, arousable only by painful stimulation)

Trial Locations

Locations (1)

South egypt cancer institute,Assiut University; 🇪🇬 Assiut, Egypt